Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Oncolytics Biotech Inc

Healthcare US ONCY

0.88USD
-0.0476(5.13%)

Last update at 2026-06-03T20:20:00Z

Day Range

0.881.00
LowHigh

52 Week Range

0.883.39
LowHigh

Fundamentals

  • Previous Close 0.93
  • Market Cap82.96M
  • Volume1549278
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-35.69500M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.29

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.75100M -26.25485M -22.50506M -33.12289M -16.48918M
Minority interest - - - - 0.00000M
Net income -24.83500M -26.30428M -19.55111M -45.55242M -17.03722M
Selling general administrative 11.49M - - 9.56M 7.24M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Ebit -28.56900M -26.23494M -25.45901M -20.69336M -16.66268M
Ebitda -28.17700M -25.66436M -27.84557M -7.59898M -16.56730M
Depreciation and amortization 0.39M 0.57M -2.38657M 13.09M 0.10M
Non operating income net other - - - - 0.00000M
Operating income -28.56900M -26.23494M -25.45901M -20.69336M -16.66268M
Other operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Interest expense 0.53M 0.14M 0.00000M 0.00000M 0.00000M
Tax provision 0.08M 0.05M 0.00000M 0.00000M 0.55M
Interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Net interest income 0.53M 0.10M 0.12M 0.18M 0.17M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.08M 0.05M -2.95395M 12.43M 0.55M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 26.92M 26.23M 25.46M 20.69M 16.66M
Cost of revenue - - - - 0.00000M
Total other income expense net 3.82M -0.01991M 2.95M -12.42953M 0.17M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Net income applicable to common shares -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 38.82M 37.33M 45.88M 34.35M 19.66M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.25M 3.02M 2.78M 2.43M 2.71M
Total liab 11.26M 10.83M 9.78M 9.59M 19.77M
Total stockholder equity 27.56M 26.50M 36.10M 24.75M -0.10789M
Deferred long term liab - - - - -
Other current liab 4.10M 1.48M 2.40M 2.46M 12.53M
Common stock 430.91M 404.04M 391.35M 356.82M 311.08M
Capital stock 430.91M 404.04M 391.35M 356.82M 311.08M
Retained earnings -446.00300M -418.25100M -393.41561M -367.11133M -344.60627M
Other liab - 6.73M 6.73M 6.73M 6.73M
Good will - - - - -
Other assets 0.00000M 1.00M - - -
Cash 31.53M 11.67M 41.26M 31.22M 14.15M
Cash and equivalents - - - - -
Total current liabilities 4.24M 3.94M 2.69M 2.71M 12.87M
Current deferred revenue -1.08200M - - - -
Net debt -31.11100M -11.29300M -40.60729M -30.81752M -13.64175M
Short term debt 0.13M 0.22M 0.29M 0.25M 0.34M
Short long term debt - - - - -
Short long term debt total 0.42M 0.37M 0.65M 0.40M 0.51M
Other stockholder equity 42.12M 40.05M 37.78M 34.64M 32.96M
Property plant equipment - 0.65M 0.98M 0.61M 0.73M
Total current assets 38.17M 35.68M 44.90M 33.74M 18.93M
Long term investments - - - - -
Net tangible assets - 26.50M 36.10M 24.75M -0.10789M
Short term investments 3.38M 20.47M - - -
Net receivables 0.01M 0.52M 0.87M 0.09M 2.07M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.08M 2.25M 1.99M 1.81M 3.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.54M 0.66M 0.39M 0.40M 0.46M
Additional paid in capital - - - - -
Common stock total equity - - - 356.82M 311.08M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M 1.00M - - 0.73M
Deferred long term asset charges - - - - -
Non current assets total 0.65M 1.65M 0.98M 0.61M 0.73M
Capital lease obligations 0.42M 0.37M 0.65M 0.40M 0.51M
Long term debt total - - - - 0.17M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.40300M -0.28595M -0.02931M -0.01090M -0.10747M
Change to liabilities 1.66M 0.18M -1.36820M 1.35M -1.31046M
Total cashflows from investing activities -20.40300M -0.28595M -0.02931M -0.01090M -0.10747M
Net borrowings -0.38100M -0.36551M -0.46072M -0.44750M -0.44750M
Total cash from financing activities 12.21M 33.02M 39.77M 21.02M 13.30M
Change to operating activities -1.61600M -0.31445M -0.40113M -1.12602M 0.46M
Net income -24.83500M -26.30428M -22.50506M -33.12289M -17.03722M
Change in cash -29.59600M 10.04M 17.07M 0.45M 1.86M
Begin period cash flow 41.26M 31.22M 14.15M 13.70M 11.84M
End period cash flow 11.67M 41.26M 31.22M 14.15M 13.70M
Total cash from operating activities -23.35500M -22.43401M -22.06844M -19.90612M -11.92024M
Issuance of capital stock 12.57M 32.91M 38.30M 18.00M 13.17M
Depreciation 0.39M 0.45M 0.45M 0.49M 0.10M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables 0.34M -0.77639M 1.98M -2.01712M 4.77M
Sale purchase of stock - - - 13.33M 12.85M
Other cashflows from financing activities 0.01M 0.47M 1.94M 3.47M 0.12M
Change to netincome 0.70M 4.33M -0.21935M 14.53M 1.12M
Capital expenditures 0.06M 0.29M 0.03M 0.01M 0.11M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital 0.39M -0.90799M 0.21M -1.79578M 3.90M
Stock based compensation 2.38M 3.83M 2.56M 1.47M 1.42M
Other non cash items -1.68100M 0.09M 0.07M 0.09M 0.08M
Free cash flow -23.41000M -22.71996M -22.09775M -19.91703M -12.02770M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ONCY
Oncolytics Biotech Inc		 -0.0476 5.13% 0.88 - - - 4.27 -1.7867
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc

322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5

Key Executives

Name Title Year Born
Dr. Matthew C. Coffey M.B.A., Ph.D. Pres, CEO & Director NA
Mr. Kirk J. Look C.A., CA Chief Financial Officer NA
Mr. Andrew R. de Guttadauro Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc 1967
Dr. Thomas C. Heineman M.D., Ph.D. Chief Medical Officer NA
Ms. Allison Hagerman P.Eng., P.M.P. VP of Product Devel. NA
Jon Patton Director of Investor Relations & Communication NA
Dr. Grey Wilkinson Ph.D. Scientist of Translational Medicine NA
Mr. John Mark Lievonen F.C.A., FCA Consultant NA
Dr. Daniel Douglas Von Hoff F.A.C.P., FACP, M.D. Consultant 1948
Dr. Matthew C. Coffey M.B.A., Ph.D. President, CEO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions